Clinical trials: Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy, Small Vessel Cerebrovascular Disease
Prognosis of Cerebral Small Vessel Disease
Prognosis of small vessel disease (SVD) depends on the underlying type of SVD and index manifestation. The aim of this prospective, observational cohort study is to determine the risk of different outcome events among patients…
- Conditions
- Cerebral Amyloid Angiopathy, Small Vessel Cerebrovascular Disease, Cadasil, CAA - Cerebral Amyloid Angiopathy
- Trial name
- PRO-SVD (NCT05734378)
- Where
- Switzerland
- Volunteers
- 900 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Cerebral Amyloid Angiopathy
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA)…
- Trial name
- cAPPricorn-1 (NCT06393712)
- Testing
- ALN-APP
- Where
- 57 sites in United States, Australia and 4 more
- Volunteers
- 210 people
- Sponsor
- Alnylam Pharmaceuticals
Cerebral Amyloid Angiopathy, Siderosis
Cerebellar Superficial Siderosis in Cerebral Amyloid Angiopathy
Cerebellar superficial siderosis (SS) has been recently reported to be present in about 10% of both hereditary (n=50) and sporadic (n=46) cerebral amyloid angiopathy (CAA) patients on 3T MRI using susceptibility-weighted imaging…
- Trial name
- CSS (NCT05394636)
- Testing
- None, pure observational study
- Where
- France
- Volunteers
- 111 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Hypertensive Arteriopathy, Cerebral Amyloid Angiopathy
Dilated Perivascular Spaces in the Dentate Nucleus on MRI in Patients With Hypertensive Angiopathy or Cerebral Amyloid Angiopathy
Hypertensive arteriopathy (HA) and cerebral amyloid angiopathy (CAA) are the two most common forms of cerebral small vessel disease.
- Trial name
- HA-DN-DPVS (NCT06888882)
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Cerebral Amyloid Angiopathy, Intracerebral Hemorrhage
MRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in CAA
In this three-year proposal, we will explore the MRI-visible EPVS in CAA and investigate its pathophysiology using animal models.
- Trial name
- CAA (NCT04604587)
- Testing
- 1. amyloid PET；2. T807 PET
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
Cerebral Amyloid Angiopathy, CAA - Cerebral Amyloid Angiopathy
Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy.
The study is divided into two phases: Phase 1 (observational) and Phase 2 (dietary intervention). The goal of Phase 1 is to assess the nutritional status and dietary habits of two cohorts of patients with CADASIL and CAA.
- Trial name
- DIETETICA (NCT06933212)
- Testing
- Mediterranean Diet with Extra Virgin Olive Oil, Mediterranean Diet with Walnuts, Low-Fat Control Diet
- Where
- Italy
- Volunteers
- 86 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Cerebral Amyloid Angiopathy
Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy
Cerebral hemorrhage, as a serious cerebrovascular disease, has the highest disability rate and mortality rate among all types of cerebrovascular diseases .It has brought a heavy burden to society.
- Trial name
- CHN-CAA (NCT07250035)
- Testing
- Jiedu Huayu Oral Prescription
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Beijing Tiantan Hospital
Cerebral Amyloid Angiopathy
A Study of AMDX-2011P in Participants With CAA
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).
- Trial name
- NCT05709314
- Testing
- AMDX-2011P
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Amydis Inc.
Cerebral Amyloid Angiopathy, Hypertensive Arteriopathy
Periventricular White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Hypertensive Arteriopathy
White matter hyperintensities (WMH) are one of the small vessel disease-related MRI characteristics of both cerebral amyloid angiopathy (CAA) and hypertensive arteriopathy (HA).
- Trial name
- PVWMH (NCT05486897)
- Testing
- None, pure observational study
- Where
- France
- Volunteers
- 315 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Amyloid Cerebral Angiopathy, Alzheimer Disease
Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis
The main objective of this study is to compare the distribution of Florbetaben (NEURACEQ: FBB) in the brain in amyloid cerebral angiopathy (ACA) manifested by isolated hemosiderosis in non-demented patients with that observed in…
- Trial name
- FBB ACC (NCT02664571)
- Testing
- Pet scan with FBB, MRI scan, APO E genotyping
- Where
- 2 sites in France
- Volunteers
- healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Intracerebral Hemorrhage, Cerebral Amyloid Angiopathy
Superficial Siderosis in Patients With Suspected Cerebral Amyloid Angiopathy
Aim of the SuSPect-CAA study is to prospectively evaluate the prognostic significance of cortical superficial siderosis in patients with suspected cerebral amyloid angiopathy with a primary focus on future stroke and mortality.
- Conditions
- Intracerebral Hemorrhage, Cerebral Amyloid Angiopathy, Ischemic Stroke
- Trial name
- SuSPect-CAA (NCT01856699)
- Where
- Germany
- Volunteers
- 302 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Cerebral Amyloid Angiopathy, Intracranial Hemorrhages
Application of Amyloid PET in Cerebral Amyloid Angiopathy
In this project, we will try to enhance the diagnostic potentials of amyloid PET in CAA by combination of dynamic amyloid PET with MRI SWI and MR perfusion images.
- Conditions
- Cerebral Amyloid Angiopathy, Intracranial Hemorrhages, Alzheimer Disease
- Trial name
- CAA (NCT03542656)
- Testing
- amyloid PET
- Where
- Taiwan
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Stroke, Neurologic Diseases, General
Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy
The main objective of this study is to evaluate the safety, tolerability and pharmacokinetics of Cerebril™ in Cerebral Amyloid Angiopathy (CAA) patients who have had lobar cerebral hemorrhage.
- Trial name
- NCT00056238
- Testing
- NC-758 (Anti amyloidotic [Aß] agent)
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bellus Health Inc. - a GSK company
Cerebral Amyloid Angiopathy
Safety and Efficacy of Remote Ischemic Conditioning on Cerebral Amyloid Angiopathy. (RIC-CAA)
Cerebral amyloid angiopathy (CAA) is a common form of cerebral small vessel disease, characterized by symptomatic intracerebral hemorrhage and cognitive impairment.
- Trial name
- NCT05207475
- Testing
- Remote ischemic conditioning
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Capital Medical University
Cerebral Amyloid Angiopathy
F-18-AV-45 Uptake, Spot Sign Presence and Cerebral Amyloid Angiopathy (CAA) in Primary Intracranial Hemorrhage (ICH)
Florbetapir F 18 is an experimental radioactive drug that may allow doctors to image changes in the brain using a PET (Positron Emission Tomography) scanner.
- Trial name
- NCT01382849
- Where
- Canada
- Sponsor
- Sunnybrook Health Sciences Centre
Cerebral Amyloid Angiopathy, CAA - Cerebral Amyloid Angiopathy
Enpowering Progression Risk of Cerebral Amyloid Angiopathy
Cerebral amyloid angiopathy (CAA) is a microangiopathy characterized by the progressive deposition of β-amyloid in cerebral vessel walls, contributing to intracerebral hemorrhages, cognitive decline, and other clinical…
- Trial name
- PRIORITY (NCT06960538)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Cerebral Amyloid Angiopathy
Balance Eyesight and Muscle Tension in the Cervical Spine in Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy (CAA) is one form of disease of the small vessels of the brain and can cause frequent cerebral hemorrhages as well as other types of stroke.
- Trial name
- NCT05082194
- Testing
- balance with open and closed eyes
- Where
- Poland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Anna Olczak
Cerebral Amyloid Angiopathy
Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy (CAA) is a condition caused by the build-up of a protein called amyloid, predominantly Aβ40, within the walls of brain blood vessels, especially those blood vessels in the occipital lobe of the brain.
- Trial name
- NCT01821118
- Testing
- Ponezumab
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 36 people
- Sponsor
- Pfizer
Cerebral Amyloid Aβ Angiopathy
Phenotypic and Molecular Characterisation of Cerebral Amyloid Angiopathy
Cerebral Aβ amyloid angiopathy is a severe disease characterised by amyloid deposits in the cerebral vessels, manifested mainly by recurrent cerebral haematomas and cognitive impairment.
- Trial name
- GENERALITY2 (NCT06864000)
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Rouen
Cerebral Amyloid Angiopathy
Cortical Superficial Siderosis and Risk of Recurrent Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy.
Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in the elderly with high risk of recurrence.
- Trial name
- CORELIA (NCT03464344)
- Testing
- neurological, neuropsychological and MRI evaluation
- Where
- 4 sites in France
- Volunteers
- 170 people
- Sponsor
- University Hospital, Toulouse